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Supplementary Table 1. Seroprevalence of co-infection with EBV or KSHV 
 
Infection EBV (N=3956) KSHV (N=3988) 
EBV - 3800 (95%) 
KSHV 3800 (96%) - 
HIV 267 (6.7%) 179 (4.5%) 
HBV 118 (2.9%) 101 (2.5%) 
HCV 151 (3.8%) 124 (3.1%) 
N represents the number of seropositive individuals 
 
Supplementary Table 2. Associations with previously identified candidate variants 
Gene Variant P1 (OR) PUG.ORF73 (b) PUG.K10.5 (b) PUG.K8.1 (b) 
IL12A rs568408 0.02 (2.4) 0.006 (-0.08) 0.81 (-
0.006) 
0.18 (-0.04) 
IL6 rs1800795 0.04 (N.R) 0.42 (-0.08) 0.91 (0.01) 0.58 (-0.05) 
IL4 rs2243248 0.05 (2.8) 0.77 (0.01) 0.96 
(0.001) 
0.64 (0.01) 
IL13 rs20541 0.01 (1.88) 0.87 (-0.004) 0.56 (-0.01) 0.62 (-0.01) 
IL8RB rs1126579 0.003(0.49) 0.87(0.01) 0.36 (0.03) 0.27(0.04) 
IL6 rs1800795 0.05 (3.7) 0.42 (-0.07) 0.91 (0.01) 0.58 (0.05) 
FCgRIIIA rs396991 0.00028 (N.R) 0.31 (-0.03) 0.93 (-
0.003) 
0.67 (-0.01) 
IRAK1 rs1059702 N.R 0.37 (0.05) 0.90 (0.05) 0.77 (0.02) 
HLA-A A*6801 0.02 (2.6) 0.38(-0.09) 0.37(-0.09) 0.08(-0.19) 
HLA-A A*30 0.019 (0.48) 0.22(-0.03) 0.21(-0.03) 0.62(-0.01) 
HLA-B B*14 0.033 (4.27)* 0.76(0.01) 0.85(-0.01) 0.83(-0.01) 
HLA-B B*58 0.00001 
(0.03) 
0.88(0.0005) 0.40(0.03) 0.49(-0.02) 
HLA-C C*0701 0.002 (1.6) 0.39(0.03) 0.16(0.04) 0.42(0.03) 
HLA-C C*05 0.0006 (0.32) 0.19(0.14) 0.15(0.16) 0.62(0.06) 
HLA-C C*07 0.01 (2.4) 0.92(-0.003) 0.68(0.01) 0.91(0.003) 
HLA-DQB1 DQB1*0502 0.0465 
(0.519) 
0.29(0.14) 0.83(-0.03) 0.56(0.08) 
HLA-DQB1 DQB1*0604  0.0017 (7.74) 0.90(-0.005) 0.73(0.01) 0.95(-0.002) 
HLA-DRB1 DRB1*04 0.02 (3.4) 0.78(-0.02) 0.24(0.09) 0.90(0.0008) 
HLA-DRB1 DRB1*1104 0.0473 (2.1) 0.19(0.17) 0.94(-
0.009) 
0.49(0.09) 
HLA-DRB1 DRB1*1302 0.0037 (5.82) 0.82(0.008) 0.59(-0.02) 0.65(0.01) 
P1 – P-value from original study  
PUG.ORF73– P-value from Uganda GPC anti-ORF73 IgG GWAS 
PUG.K8.1 – P-value from Uganda GPC anti-K8.1 IgG GWAS 
PUG.K10.5 – P-value from Uganda GPC anti-K10.5 IgG GWAS 
N.R – Not reported 
*FDR (False Discovery Rate)
Supplementary Table 3. Loci with significant evidence of association with anti-EBV IgG levels (N=3,289)   
Trait Chr:Pos(b37) Variant Nearest Genea Consequencea EA EAF (%) P  b (95% C.I) 
EBNA-1 6:32604654 rs9272371 HLA-DQA1 Intron C 26.9 5.24x10-33 -0.37 (-0.43 – -0.31) 
EBNA-1 6:32404220 rs3129867 HLA-DRA Upstream G 49.2 1.63x10-22* -0.25(-0.30 - -0.20) 
VCA 6: 32615738 rs28394498 HLA-DQA1 Intron T 17.9 9.15x10-11 -0.23 (-.29 - -0.16) 
EA – Effect Allele, EAF – Effect Allele Frequency 
     
aAnnotated using Ensembl VEP 
      
*P.conditional on lead SNP, b (95%C.I)=6.01 x10-11, -0.17(-0.22 - -0.12) 
    
  
Supplementary Table 4. Credible set showing strong evidence of association with anti-EBNA-1 IgG levels after meta-analysis  
  Alleles Ugandan (N=4365) European Ancestry (N=2162) MANTRA 
 EUR + UG (N=6527) 
Lead SNP Chr:Pos(b37) Locus Effect/ 
Other 
EAF Beta SE P EAF Beta SE P log10BF PQ* 
rs6927022a 6:32612397 HLA-
DRB1 
A/G 0.73 0.26 0.02 1.36x10-21 0.59 0.16 0.015 7.35x10-26 44.3 0.06 
rs9272371b 6:32604654 HLA-
DQA1 
C/T 0.3 -0.36 0.02 3.63x10-44 0.37 -0.02 0.015 0.14 42.6 3.56x10-
8 
rs9274247 6:32631295 HLA-
DQB1 
A/G 0.22 -0.32 0.02 2.63x10-29 0.35 -0.13 0.015 4.51x10-16 42.2 0.63 
EAF - Effect Allele Frequency              
SE – Standard Error              
aEuropean (EUR) lead SNP              
bUgandan (UG) lead SNP              
*PQ – Cochran’s Q-test for heterogeneity              
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Supplementary Figure 1. Burden of viral infections tested in the GPC Round 22 (2011). The number 
of seropositive reactions to viruses for all participants, the infection count represents the minimum 
number of infections participants are seropositive for. 
 
 Supplementary Figure 2. Correlation matrix of antibody responses (MFI) for KSHV and EBV. Positive 
correlations are in blue and intensity is proportional to the correlation coefficients (r2) labelled in the 
squares and indicated on the right-hand side of the correlogram. All tests meet Pearson’s significance 
threshold of p<0.05. 
  
Supplementary Figure 3. Genome-wide association QQ-plots of all IgG response levels in 4,365 
individuals. A. Anti-Orf73 IgG association. B. Anti-K8.1 IgG association. C. Anti-K10.5 IgG 
association. D. Anti-EBNA-1 IgG association. E. Anti-VCA IgG association. 
 
 
 
 
 
 
 Supplementary Figure 4. Genome-wide association results of anti-KSHV IgG response levels in 4,365 
individuals. A. Anti-ORF73 IgG association. B. Anti-K8.1 IgG association. C. Anti-K10.5 IgG 
association. GWAS performed using linear mixed model accounting for kinship in GEMMA. Red 
dashed line: Genome wide significance threshold (p<1x10-8), grey dashed line: Standard genome-
wide significance threshold (p<5x10-8), 23=X Chromosome. Yellow: SNPs that meet the standard 
genome-wide significance threshold (p<5x10-8).  
 
 
 Supplementary Figure 5. Genome-wide association results of anti-EBV IgG response levels in 4,365 
individuals. A. Anti-EBNA-1 IgG association. B. Anti-VCA IgG association. Manhattan Plot: Grey 
dashed line: Genome wide significance threshold (p<1x10-8), 23=X Chromosome. Yellow: SNPs that 
meet the genome-wide significance threshold. 
 
 Supplementary Figure 6. Trans-ethnic meta-analysis association plot for EBNA-1 IgG response levels 
in 6152 individuals of Ugandan and European Ancestry (EUR). The lead SNPs for EUR (rs6927022, 
log10BF= 44.3) and Uganda (rs9272371, log10BF= 42.6) GWASs on chromosome 6 within the HLA 
region are labelled and circled in purple. Grey dashed line: threshold= log10BF > 6. Yellow: SNPs that 
meet the statistical significance threshold. 
